Terms: = Thyroid cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
203 results:
1. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
2. DNA Methylation-Regulated HOXC8's Role in her2-Positive Breast cancer Function and its Contribution to Herceptin Resistance.
Xie X; Tang S; Yu Z
Discov Med; 2024 Mar; 36(182):559-570. PubMed ID: 38531796
[TBL] [Abstract] [Full Text] [Related]
3. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast cancer Society Clinical Practice Guidelines.
Hattori M; Honma N; Nagai S; Narui K; Shigechi T; Ozaki Y; Yoshida M; Sakatani T; Sasaki E; Tanabe Y; Tsurutani J; Takano T; Saji S; Masuda S; Horii R; Tsuda H; Yamaguchi R; Toyama T; Yamauchi C; Toi M; Yamamoto Y
Breast Cancer; 2024 May; 31(3):335-339. PubMed ID: 38433181
[TBL] [Abstract] [Full Text] [Related]
4. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
[TBL] [Abstract] [Full Text] [Related]
5. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast cancer Registry.
Iwamoto T; Kumamaru H; Niikura N; Sagara Y; Miyashita M; Konishi T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Watanabe C; Kinukawa N; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):185-194. PubMed ID: 38319565
[TBL] [Abstract] [Full Text] [Related]
6. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in her2-positive breast cancer.
Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of Disease-Free Survival in Breast cancer using Deep Learning with Ultrasound and Mammography: A Multicenter Study.
Han J; Hua H; Fei J; Liu J; Guo Y; Ma W; Chen J
Clin Breast Cancer; 2024 Apr; 24(3):215-226. PubMed ID: 38281863
[TBL] [Abstract] [Full Text] [Related]
8. thyroid Ultrasound Image Database and Marker Mask Inpainting Method for Research and Development.
Li X; Fu C; Xu S; Sham CW
Ultrasound Med Biol; 2024 Apr; 50(4):509-519. PubMed ID: 38267314
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of first-line therapy in patients with her2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Wang J; Yu Y; Lin Q; Zhang J; Song C
J Cancer Res Clin Oncol; 2024 Jan; 150(1):21. PubMed ID: 38244085
[TBL] [Abstract] [Full Text] [Related]
10. Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.
Guo L; Cheng H; Liu J; Shao W; Luo L; Zheng W; Sun S; Kong D; Chen C
BMC Med Genomics; 2024 Jan; 17(1):25. PubMed ID: 38243282
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of baseline neutrophil/lymphocyte ratio in her2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
Ding N; Pang J; Liu X; He X; Zhou W; Xie H; Feng J; Wang G; Tang J; Cao J; He L; He Y; Wang S; Xiao Z
Breast Cancer Res; 2024 Jan; 26(1):9. PubMed ID: 38212845
[TBL] [Abstract] [Full Text] [Related]
12. 2020 Annual Report of National Clinical Database-Breast cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Sagara Y; Kumamaru H; Niikura N; Miyashita M; Konishi T; Iwamoto T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Kinukawa N; Watanabe C; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):179-184. PubMed ID: 38180641
[TBL] [Abstract] [Full Text] [Related]
13. Contrast-Enhanced Ultrasound and Conventional Ultrasound Characteristics of Breast cancer With Different Molecular Subtypes.
Li X; Zhang J; Zhang G; Liu J; Tang C; Chen K; Chen P; Tan L; Guo Y
Clin Breast Cancer; 2024 Apr; 24(3):204-214. PubMed ID: 38102010
[TBL] [Abstract] [Full Text] [Related]
14. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2024 Jan; 203(2):225-234. PubMed ID: 37875670
[TBL] [Abstract] [Full Text] [Related]
15. Research Status of Systemic Adjuvant Therapy for Early Breast cancer.
Hu W; Xu D; Li N
Cancer Control; 2023; 30():10732748231209193. PubMed ID: 37864566
[TBL] [Abstract] [Full Text] [Related]
16. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing her-2 protein expression and mRNA stability by binding to HUR.
Liu C; Lu C; Yixi L; Hong J; Dong F; Ruan S; Hu T; Zhao X
Breast Cancer Res; 2023 Oct; 25(1):124. PubMed ID: 37848981
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant Chemotherapy of Taxanes With or Without Anthracyclines in Different Molecular Subtypes of Breast cancer: A Propensity Score Matching Study.
Xiao J; Wang T; Yi J; Huang M; Yan C; Ling R
Clin Breast Cancer; 2023 Dec; 23(8):882-893. PubMed ID: 37833133
[TBL] [Abstract] [Full Text] [Related]
18. Advanced hormone receptor-positive/human epidermal growth factor receptor 2-positive invasive ductal carcinoma with cecal metastasis: A case report.
Yang SY; Zhang J; Yang ZQ; Duan JJ; Zhang Y; Li MK; Wang L; Ye CM; Nie JY
Sci Prog; 2023; 106(4):368504231201043. PubMed ID: 37828835
[TBL] [Abstract] [Full Text] [Related]
19. Pyrotinib-based therapeutic approaches for her2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract] [Full Text] [Related]
20. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/her-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
[TBL] [Abstract] [Full Text] [Related]
[Next]